Acquisition by Sing George L of 1958 shares of Regeneron Pharmaceuticals at 719.37 subject to Rule 16b-3
REGN Stock | USD 718.15 2.96 0.41% |
About 56% of Regeneron Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Regeneron Pharmaceuticals suggests that many traders are alarmed. Regeneron Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in Regeneron Pharmaceuticals. Many technical investors use Regeneron Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Regeneron |
Filed transaction by Regeneron Pharmaceuticals Director. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at finance.yahoo.com
Regeneron Pharmaceuticals Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Regeneron Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Regeneron Pharmaceuticals Fundamental Analysis
We analyze Regeneron Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Regeneron Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Regeneron Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Valuation
Current Valuation Comparative Analysis
Regeneron Pharmaceuticals is currently under evaluation in current valuation category among its peers. Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Regeneron Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Regeneron Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Regeneron Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Regeneron Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Regeneron Pharmaceuticals Related Equities
MDGL | Madrigal Pharmaceuticals | 1.88 | ||||
SRPT | Sarepta Therapeutics | 1.77 | ||||
PTCT | PTC Therapeutics | 1.44 | ||||
KRYS | Krystal Biotech | 1.17 | ||||
APLS | Apellis Pharmaceuticals | 0.90 | ||||
RARE | Ultragenyx | 0.85 | ||||
ARWR | Arrowhead Pharmaceuticals | 0.71 | ||||
BMRN | Biomarin Pharmaceutical | 0.51 | ||||
BGNE | BeiGene | 0.39 | ||||
IONS | Ionis Pharmaceuticals | 0.35 | ||||
ALNY | Alnylam Pharmaceuticals | 0.28 | ||||
NVO | Novo Nordisk | 0.15 | ||||
INCY | Incyte | 0.14 | ||||
NTLA | Intellia Therapeutics | 0.74 | ||||
CRSP | Crispr Therapeutics | 0.99 | ||||
UTHR | United Therapeutics | 1.08 |
Check out Regeneron Pharmaceuticals Hype Analysis, Regeneron Pharmaceuticals Correlation and Regeneron Pharmaceuticals Performance. To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.298 | Earnings Share 40.43 | Revenue Per Share | Quarterly Revenue Growth 0.106 | Return On Assets |
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Regeneron Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.